Australia recorded 118 notifications of invasive meningococcal disease (IMD) in 2025, a reduction of 13% compared with 2024, investigators reported. The surveillance case count included both probable and laboratory-confirmed reports submitted to the National Notifiable Diseases Surveillance System. Laboratory confirmation was present in 115 of the 118 reported IMD cases (97%), leaving three notifications classified as probable without laboratory confirmation reported in the abstract.
Case ascertainment relied heavily on laboratory diagnostics. Two diagnostic pathways were reported: bacterial culture accounted for 66% of confirmed diagnoses (76/115), and nucleic acid amplification testing contributed 34% (39/115). The abstract did not provide further breakdown by specimen type, collection timing, or clinical presentation.
The genogroup was determined for 93% (107/115) of laboratory-confirmed cases. Data indicated a dominant prevalence of MenB, which made up 82.2% (88/107) of genogrouped infections. Smaller proportions were attributed to MenW and MenY, each representing 7.5% (8/107). MenC accounted for 1.9% (2/107), and a single case (0.9%) was genogroup MenA.
Finetyping results were available for 67% (72/107) of cases with an assigned genogroup. Among the MenB isolates that were finetyped (58 isolates reported in that subgroup), 28 distinct porA types were identified. The most frequent porA types in finetyped MenB isolates were P1.7-2,4 (21%; 12/58) and P1.7,16-26 (14%; 8/58). The report lists those porA prevalences but did not include sequence data beyond porA nor detailed antigenic profiles in the abstract.
Of eight MenW isolates in 2025, six were finetyped. These six were identified as porA type P1.5,2, multilocus sequence type (MLST) ST11 and assigned to clonal complex 11. The authors noted this lineage corresponds to the hypervirulent ST11 clonal complex implicated in outbreaks both within Australia and internationally. For MenY, five isolates were finetyped and displayed four porA types (P1.21,16; P1.5,10-1; P1.5-1,10-1; P1.5-2,10-1) without a single dominant pattern. One of the two MenC isolates was typed as P1.5-2,10-1 and the single MenA isolate was reported as P1.5-2,10.
Age-grouped incidence showed distinct peaks. Children younger than 5 years comprised 18% (21/115) of laboratory-confirmed IMD, young adults aged 15–24 years contributed 23% (26/115), and adults aged 25–44 years accounted for 22% (25/115). Cases occurred across all age ranges captured by surveillance: 5–9 years (5%; 6/115), 10–14 years (2.6%; 3/115), 45–64 years (12%; 14/115), and 65 years and older (17%; 20/115).
Genogroup distribution varied by age. The cohort showed that 100% of IMD in children under 5 years (21/21) and in those aged 15–24 years (25/25; note: abstract lists 25/25 for that genogroup subset) were attributed to MenB. In adults aged 25–44 years, MenB comprised 82% (18/22) of IMD in that age group; the remainder included three MenW and one MenC case. The majority of MenY infections (6/8) were reported in people aged 65 years and older; in that older group MenY accounted for 33% (6/18) of IMD.
All cultured IMD isolates available for susceptibility testing (n = 76) underwent testing for ceftriaxone and penicillin, with minimum inhibitory concentrations (MICs) interpreted using Clinical Laboratory Standards Institute (CLSI) criteria. Penicillin results were distributed as follows: 8% (6/76) met the report’s threshold for penicillin resistance (MIC ≥ 0.5 mg/L); 64% (49/76) demonstrated intermediate susceptibility (MIC values of 0.125–0.25 mg/L); and 28% (21/76) were penicillin susceptible (MIC ≤ 0.064 mg/L).
The surveillance testing found universal susceptibility among tested isolates to ceftriaxone, ciprofloxacin and rifampicin. The abstract does not provide MIC ranges for these agents, nor does it list the testing methodology beyond CLSI interpretative criteria for MICs.
The report presents surveillance totals, genogroup distributions, finetyping snapshots and antimicrobial susceptibility summaries. The abstract did not include clinical outcomes (for example, mortality or sequelae), treatment regimens used, or detailed molecular methods beyond porA and MLST annotations where provided. It did not specify geographic breakdowns within Australia or timelines of specimen collection. These omissions limit interpretation of clinical severity, temporal trends at finer resolution, and potential vaccine impact analyses within the dataset. Future reports would need to provide those data elements to address questions about outcome correlations, temporal shifts in finetypes, and the public health implications of the observed penicillin intermediate and resistant proportions.